Wounds and Injuries
Conditions
Keywords
Donor, Skin Graft, Wound, Partial Thickness
Brief summary
A study to to evaluate the efficacy of Microlyte® Matrix by demonstrating its superiority to the standard of care in the healing of donor site wounds in patients requiring split-thickness grafting, as well as to assess the occurrence of donor site wound infection, allergic reaction, pain and itching, and scarring at 12 weeks, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).
Detailed description
The proposed study is a randomized, controlled, open-label clinical trial to assess the efficacy in wound healing of the FDA 510k cleared Microlyte® Matrix (K153756) in surgically created partial thickness donor site wounds \> 100 cm2 in size on patients and harvested at 12/1000th inch requiring split-thickness skin grafting. Subjects are expected to be hospitalized as in-patients for approximately 7 days following initial donor site surgery. Study visits conducted after hospital discharge must be conducted as out-patient clinic visits. Each wound will be divided into proximal and distal halves with one half randomized to receive Microlyte® Matrix. Kaltostat/Tegaderm will be used as the control. Thus, each patient is their own control removing the potential variability of the depth of donor site wounds between patients as a confounding factor. Microlyte® Matrix is a FDA-cleared (K153756) antimicrobial dressing manufactured by Imbed Biosciences, Inc. (Madison, WI), which is an ISO 13485 certified/FDA QSR compliant facility. It is indicated for the management of partial and full thickness wounds including pressure ulcers, venous stasis ulcers, diabetic foot ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds.
Interventions
DEVICEMicrolyte® Matrix
Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
Sponsors
Arizona Burn Center, Maricopa Medical Center (Phoenix, AZ)
Imbed Biosciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
The primary outcome assessment in this trial will be assessed by digital photography of the wounds as assessed by study team members who are blinded to the randomization.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical/traumatic wound, and tumor excision. 2. Donor site wound with a surface area of greater than 100 cm2 is required. 3. At least 18 years of age 4. Provision of signed and dated informed consent form 5. Stated willingness to comply with all study procedures and availability for the duration of the study 6. Ability and willingness to adhere to the study intervention regimen and follow-up visits
Exclusion criteria
1. Age less than 18 years. 2. Vulnerable population. 3. Pregnant, lactating or nursing women. 4. Unable to provide consent. 5. Presumed unable to complete follow-up assessments. 6. Prior adverse reaction or sensitivity to silver. 7. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study. 8. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc. 9. Any diagnosis with concern for 30 Day mortality.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of donor site wound closure | Day 14 post-op | Therefore, assessment of the percentage wound closure at the time of primary outcome assessment (14 days) provides a very reliable method for detection of differences between groups. Digital photography and Image-J analysis allow for blinded assessment of primary outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of donor site wound closure | Day 7 post-op | Signs of infection or allergic reactions, pain, and pruritus assessed during each study visit. |
| Durability of wound closure, assessed by percentage of wound closure | 12 weeks | Wound Closure ranges from 0%-100% with 0% being no wound closure occurring and 100% being full closure |
| Pain, itching, and scarring, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS). | 12 weeks | POSAS Scale is a series of questions with answers ranging from 1-10, with 1 dictating few or negligible differences from normal skin, and 10 being unimaginable scar difference from normal skin. |
| Signs of infection or allergic reactions, pain, and pruritus | 12 weeks | — |
Outcome results
None listed